1[1]Rohringer M, Sutherland GR, Louw DF, et al. Incidence and clinicopathogical features of meningioma[J].J Neurosurg, 1989,71(5 pt 1):665～72.
2[2]Adegbite A.B, Khan MI, Paine K WE, et al. The recurrence of intracranial meningiomas after surgical treatment[J].J Neurosurg,1983,58(1):51～6.
3[3]Moller ML, Braendstrup O. No prediction of recurrence of meningiomas by PCNA and Ki-67 immunohistochemistry[J]. J Neurooncol,1997,34(3):241～6.
4[4]Hiraga S, Ohnishi T, Izamoto S, et al. Telomerase activity and alterations in telomere length in human brain tumors[J]. Cancer Res,1998,58(10):2117～25.
5[5]DeMasters BK, Markham N, Lillehei KO, et al. Differential telomerase expression in human primary intracranial[J]. Am J Clin Pathology, 1997,107(5):548～54.
6[7]Takeuchi H, Kubota T, Kabuto M, et al. Prediction of recurrence in histologically benign meningiomas: proliferating cell nuclear antigen and Ki-67 immunohistochemical study[J]. Surg Neurol,1997,48(5):501～6.
7[8]Landberg G,Nielsen NH, Nilsson P, et al.Telomerase activity is associated with cell cycle deregulation in human breast cancer[J]. Cancer Res, 1997,57(3):549～54.
8Marija Zeremski,Stephen K. Horrigan,Irina A. Grigorian,Carol A. Westbrook,Andrei V. Gudkov. Localization of the candidate tumor suppressor geneING1 to human chromosome 13q34[J] 1997,Somatic Cell and Molecular Genetics(3):233～236
